Physician profile
Mark T Burbridge
NPI 1477749208
$5,874.36
in general payments reported to CMS, 2019-2025
55 companies · $1,615 in 2025
The $1,615 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $157 · 2020: $117 · 2021: $320 · 2022: $837 · 2023: $1,558 · 2024: $1,269 · 2025: $1,615.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,442.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,442.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $947.19 | 2021-2025 | |
| Gilead Sciences, INC. | $419.48 | 2021-2025 | Trodelvy |
| Merck Sharp & Dohme LLC | $377.96 | 2019-2025 | Keytruda, Lynparza, Welireg |
| E.R. Squibb & Sons, L.L.C. | $325.41 | 2020-2025 | Opdivo, Eliquis, Opdualag |
| Daiichi Sankyo INC. | $298.45 | 2021-2025 | Enhertu, Injectafer, Datroway |
| Pfizer INC. | $265.73 | 2022-2025 | |
| Janssen Biotech, INC. | $252.33 | 2019-2025 | Erleada, Akeega, Balversa |
| Celgene Corporation | $222.78 | 2022-2025 | Reblozyl, Pomalyst |
| Genzyme Corporation | $203.27 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $179.19 | 2019-2025 | Calquence, Lynparza |
| Glaxosmithkline, LLC. | $163.50 | 2022-2025 | Ojjaara, Blenrep, Zejula |
| Amgen INC. | $150.34 | 2019-2023 | Blincyto, Kyprolis |
| Jazz Pharmaceuticals INC. | $146.52 | 2021-2025 | |
| Genentech USA, INC. | $144.16 | 2020-2025 | Venclexta, Polivy, Tecentriq |
| Lilly USA, LLC | $115.53 | 2019-2024 | Verzenio, Jaypirca, Retevmo |
Show all 55 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $110.17 | 2024-2025 | Monjuvi, Pemazyre, Jakafi |
| Puma Biotechnology, INC. | $97.10 | 2023-2025 | |
| Adc Therapeutics America, INC. | $86.59 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $74.07 | 2024-2025 | Ninlaro, Fruzaqla |
| Alnylam Pharmaceuticals INC. | $68.45 | 2022-2025 | Givlaari |
| Array Biopharma INC | $67.63 | 2024-2025 | Lorbrena, Braftovi, Mektovi |
| Deciphera Pharmaceuticals INC. | $64.40 | 2022-2025 | Qinlock, Romvimza |
| Seagen INC. | $63.80 | 2021-2023 | Adcetris, Tukysa |
| Regeneron Healthcare Solutions, INC. | $63.22 | 2020-2025 | Libtayo |
| Emd Serono, INC. | $62.83 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $60.30 | 2023-2025 | |
| Servier Pharmaceuticals LLC | $58.50 | 2021-2024 | |
| Alexion Pharmaceuticals, INC. | $52.97 | 2022-2025 | Ultomiris |
| Beigene USA, INC. | $46.23 | 2023 | Brukinsa |
| Pharmacosmos Therapeutics INC. | $43.47 | 2022-2024 | Monoferric |
| Blue Earth Diagnostics | $42.33 | 2021-2023 | |
| G1 Therapeutics, INC. | $40.82 | 2023 | Cosela |
| Mirati Therapeutics, INC. | $40.71 | 2023-2024 | Krazati |
| Medtronic, INC. | $40.08 | 2023 | Osteocool Rf Ablation System |
| Dendreon Pharmaceuticals LLC | $33.99 | 2025 | Provenge |
| Iovance Biotherapeutics, INC. | $31.37 | 2025 | Amtagvi |
| Astellas Pharma US INC | $28.75 | 2025 | Vyloy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.74 | 2025 | |
| Tempus Ai, INC | $27.05 | 2024 | Xt Cdx |
| Invivyd INC | $25.61 | 2025 | Pemgarda |
| Pharmaessentia USA Corporation | $25.26 | 2023 | Besremi |
| Genmab U.S., INC. | $25.04 | 2024 | Epkinly |
| Fresenius Kabi USA, LLC | $24.85 | 2025 | Stimufend |
| Acrotech Biopharma INC. | $23.16 | 2023 | Beleodaq |
| Ipsen Biopharmaceuticals, INC | $22.91 | 2023 | Somatuline Depot, Onivyde |
| Eisai INC. | $21.93 | 2024 | |
| Abbvie INC. | $21.34 | 2025 | |
| Tg Therapeutics, INC. | $19.78 | 2021 | |
| Agios Pharmaceuticals, INC. | $19.25 | 2024 | Pyrukynd |
| Dova Pharmaceuticals | $19.16 | 2021 | |
| Tersera Therapeutics LLC | $18.67 | 2025 | Xermelo |
| Janssen Pharmaceuticals, INC | $16.72 | 2019 | |
| Kyowa Kirin, INC. | $16.40 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $14.55 | 2023 | Sancuso |
| Rigel Pharmaceuticals, INC. | $14.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Burbridge listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.